Takeda Pharmaceutical Co Ltd (TKPHF) stock

TKPHFOTCPharmaceutical PreparationsAlso trades as TAK

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30

$39.00+0.36 (+0.93%)

Close on Oct 19, 2026Market cap $134.41BP/E –Yield –

Takeda Pharmaceutical free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2026 it was ¥865.43B, up 1.1% from the year before. The highest annual figure on record is ¥999.85B in fiscal 2022.

Period	Period end	Value	Change
FY2026	Mar 31, 2026	¥865.43B	+1.1%
FY2025	Mar 31, 2025	¥856.39B	+58.3%
FY2024	Mar 31, 2024	¥540.92B	-35.3%
FY2023	Mar 31, 2023	¥836.50B	-16.3%
FY2022	Mar 31, 2022	¥999.85B	+11.1%
FY2021	Mar 31, 2021	¥899.73B	+65.8%
FY2020	Mar 31, 2020	¥542.67B	+116.4%
FY2019	Mar 31, 2019	¥250.80B	-19.3%
FY2018	Mar 31, 2018	¥310.85B	+55.7%
FY2017	Mar 31, 2017	¥199.70B	–

Parsed from the XBRL in Takeda Pharmaceutical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TKPHF.

Revenue growth-1.7% · median 16.2%

Gross margin65.1% · median 78.4%

Net margin-3.4% · median 19.3%

Advertisement
300 × 250